PETACH TIKVA, Israel - PolyPid Ltd. (NASDAQ:PYPD), a late-stage biopharma company, has reported findings from the Phase 3 SHIELD I trial evaluating D-PLEX100, a local prolonged-release doxycycline, for the prevention of surgical site infections (SSIs) in abdominal colorectal surgery. The results, published in the International Journal of Surgery, indicate that while the primary endpoint was not met due to an unexpected change in baseline infection rates during the COVID-19 pandemic, D-PLEX100 may benefit patients with increased SSI risk, particularly those with incisions longer than 20 cm.
The multinational, randomized, double-blind trial enrolled 977 patients from over 60 centers in the United States, Europe, and Israel. Although the overall reduction in infection events with D-PLEX100 was not statistically significant, a pre-specified subgroup analysis showed a 54% reduction in SSIs for incisions greater than 20 cm treated with D-PLEX100 compared to standard care. The exploratory analysis also suggested potential benefits of D-PLEX100 in reducing the need for surgical reintervention.
No safety concerns were raised, and the incidence of treatment-emergent adverse events was similar between the D-PLEX100 and standard of care arms. The ongoing SHIELD II study continues to assess the efficacy and safety of D-PLEX100 in a similar patient population with large surgical incisions, with top-line results expected in the first quarter of 2025.
D-PLEX100 utilizes PolyPid's PLEX technology to provide a high local concentration of doxycycline at the surgical site for 30 days, potentially preventing SSIs, including those caused by antibiotic-resistant bacteria. The U.S. Food and Drug Administration has granted D-PLEX100 Breakthrough Therapy Designation for the prevention of SSIs in elective colorectal surgery.
This article is based on a press release statement from PolyPid Ltd. and does not include any speculative information or broader industry impacts.
In other recent news, PolyPid Ltd. has reported a net loss of $6.3 million in the second quarter of 2024, marking an increase from the previous year's $5.8 million loss for the same period. Despite the loss, the company has secured $8.1 million in financing. A significant development for the company is the completion of patient enrollment for the interim analysis phase of its SHIELD II trial. The trial, which is testing D-PLEX100, PolyPid's leading drug candidate, has enrolled approximately 430 patients to date. H.C. Wainwright, maintaining its Buy rating and $14.00 stock price target for PolyPid, anticipates the interim review will recommend the trial to continue as scheduled, with final top-line results projected to be available in the first quarter of 2025. In other company developments, PolyPid has promoted Dalit Hazan to Deputy CEO and held an event focused on preventing surgical site infections. These are the recent developments that underline the company's ongoing efforts in its clinical trials and leadership changes.
InvestingPro Insights
As PolyPid Ltd. (NASDAQ:PYPD) continues to develop its D-PLEX100 technology, investors should be aware of some key financial metrics and insights provided by InvestingPro.
The company's market capitalization stands at a modest $24.42 million, reflecting its status as a late-stage biopharma company still in the development phase. This aligns with the ongoing Phase 3 trials for D-PLEX100 mentioned in the article.
InvestingPro Data shows that PolyPid's operating income for the last twelve months as of Q2 2023 was -$23.68 million, indicating that the company is currently operating at a loss. This is not unusual for biotech companies in the research and development stage, especially those conducting expensive clinical trials like the SHIELD I and II studies.
Two relevant InvestingPro Tips highlight that PolyPid is "quickly burning through cash" and "not profitable over the last twelve months." These points underscore the financial challenges faced by the company as it pursues its clinical development programs, including the ongoing SHIELD II study mentioned in the article.
It's worth noting that despite these financial challenges, InvestingPro reports that 2 analysts have revised their earnings upwards for the upcoming period. This could potentially reflect optimism about the company's future prospects, possibly related to the potential benefits of D-PLEX100 in reducing surgical site infections for certain patient groups, as indicated in the SHIELD I trial results.
For investors interested in a more comprehensive analysis, InvestingPro offers 6 additional tips for PolyPid, providing a deeper understanding of the company's financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.